Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis

Documenti analoghi

• Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry
  di: Filip Rob, et al.
  Pubblicazione: (2025)
• Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab
  di: Mizuki Shiba, et al.
  Pubblicazione: (2026)
• Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies
  di: Elena Ippoliti, et al.
  Pubblicazione: (2025)
• Real‐World Effectiveness and Safety of Lebrikizumab in Moderate‐to‐Severe Atopic Dermatitis: A Multicenter Study From Spain
  di: Jose Carlos Armario‐Hita, et al.
  Pubblicazione: (2025)
• Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
  di: Asia Batool, et al.
  Pubblicazione: (2026)